Jetzt wird Talon zum Big Player - 500 Beiträge pro Seite
eröffnet am 29.08.11 16:17:49 von
neuester Beitrag 31.08.11 21:38:55 von
neuester Beitrag 31.08.11 21:38:55 von
Beiträge: 8
ID: 1.168.668
ID: 1.168.668
Aufrufe heute: 0
Gesamt: 746
Gesamt: 746
Aktive User: 0
ISIN: US87484H1041 · WKN: A1H4LB
Feedback
Wahnsinns News
http://www.otcmarkets.com/stock/TLON/news
Geht gut ab viel erfolg für alle die durchgehalten haben
Antwort auf Beitrag Nr.: 42.016.383 von kafutznik am 29.08.11 16:17:49Talon Therapeutics Receives Special Protocol Assessment Agreement from the Food and Drug Administration for Its Phase 3 Confirmatory Study of Marqibo(R) in Newly Diagnosed Acute Lymphoblastic Leukemia
SAN MATEO, Calif., Aug. 29, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON.OB - News), announced today the company has reached agreement with the U. S. Food and Drug Administration (FDA) regarding a special protocol assessment (SPA) for its planned Phase 3 study of Marqibo(R) (vincristine sulfate liposomes injection) in adults with newly diagnosed Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).
Talon submitted a new drug application (NDA) to the FDA in July 2011 seeking accelerated approval of Marqibo in adult Ph- ALL, in second or greater relapse or that has progressed following two or more prior lines of anti-leukemia therapy. The Phase 3 study now under SPA, named HALLMARQ (Halting newly diagnosed Adult acute Lymphoblastic Leukemia with Marqibo containing chemotherapy), is intended to be a confirmatory study to be completed following the accelerated approval of Marqibo. Talon expects to know if the NDA has been accepted for filing by the FDA in mid-September 2011.
"Receiving an SPA from the FDA is a major accomplishment for Talon. The SPA represents a written agreement between Talon and the FDA regarding the planned design, conduct, and analysis of our Phase 3 ALL trial called HALLMARQ," stated Steven R. Deitcher, President, Chief Executive Officer and Board Member of Talon Therapeutics. "HALLMARQ will be a global trial with initial clinical site openings expected in the US prior to the end of 2011."
About the HALLMARQ Study
Title: "A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo (Vincrisitne Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects >= 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)."
Primary Objective: To compare overall survival (OS) among subjects 60 years of age and older with newly diagnosed ALL who receive Marqibo versus standard vincristine as a component of multi-agent induction, intensification, and maintenance chemotherapy. The study is powered for superiority.
Study Design and Methodology: Eligible subjects will be randomized to a standardized and widely accepted combination chemotherapy regimen containing either VSI or Marqibo. Treatment will be divided into induction, intensification, and maintenance phases of therapy. The sample size is event driven with a projected total enrollment of 350 to 400 patients.
About Marqibo
Marqibo is a novel, targeted Optisome(TM) encapsulated formulation product candidate of the FDA-approved anticancer drug vincristine. Talon has been primarily developing Marqibo for the treatment of adult, Ph- ALL. Vincristine, a microtubule inhibitor, is FDA-approved for ALL and is widely used as a single agent and in combination regimens for treatment for hematologic malignancies such as lymphomas and leukemias. Talon's encapsulation formulation is designed to provide prolonged circulation of the drug in the blood and accumulation at the tumor site. These characteristics are intended to increase the dose of vincristine delivered in a safe and effective manner.
About Talon Therapeutics
Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
In addition to Marqibo, the Company has additional pipeline opportunities some of which, like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.
Additional information on Talon Therapeutics can be found at www.talontx.com.
The Talon Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include without limitation, statements regarding Talon's ability to obtain accelerated approval of Marqibo for the treatment of adult Ph- ALL, the potential of Marqibo to be a safe and effective alternative for existing therapies, the timing of initiating Talon's proposed Phase 3 clinical trial of Marqibo, and the timing, progress and anticipated results of the clinical development of Marqibo and Talon's other product candidates. Such statements involve risks and uncertainties that could cause Talon's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Such risks and uncertainties include: that there can be no assurances that any of Talon's clinical and regulatory development efforts relating to Marqibo will be successful; that Talon's NDA for Marqibo will be accepted for filing by the FDA and, even if the NDA is accepted by the FDA, that it will be approved; that the data of the clinical trials of Marqibo will be sufficient to support approval by the FDA of the NDA for Marqibo; that the results of the clinical trials of Marqibo will support Talon's claims or beliefs concerning Marqibo's safety and effectiveness; that Talon will be able to secure the additional capital necessary to fund its product development programs, including Marqibo, to completion; Talon's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2010. Talon assumes no obligation to update these statements, except as required by law.
Contact:
Investor & Media Contacts:
Investor Relations Team
(650) 588-6641
investor.relations@talontx.com
SAN MATEO, Calif., Aug. 29, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON.OB - News), announced today the company has reached agreement with the U. S. Food and Drug Administration (FDA) regarding a special protocol assessment (SPA) for its planned Phase 3 study of Marqibo(R) (vincristine sulfate liposomes injection) in adults with newly diagnosed Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).
Talon submitted a new drug application (NDA) to the FDA in July 2011 seeking accelerated approval of Marqibo in adult Ph- ALL, in second or greater relapse or that has progressed following two or more prior lines of anti-leukemia therapy. The Phase 3 study now under SPA, named HALLMARQ (Halting newly diagnosed Adult acute Lymphoblastic Leukemia with Marqibo containing chemotherapy), is intended to be a confirmatory study to be completed following the accelerated approval of Marqibo. Talon expects to know if the NDA has been accepted for filing by the FDA in mid-September 2011.
"Receiving an SPA from the FDA is a major accomplishment for Talon. The SPA represents a written agreement between Talon and the FDA regarding the planned design, conduct, and analysis of our Phase 3 ALL trial called HALLMARQ," stated Steven R. Deitcher, President, Chief Executive Officer and Board Member of Talon Therapeutics. "HALLMARQ will be a global trial with initial clinical site openings expected in the US prior to the end of 2011."
About the HALLMARQ Study
Title: "A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo (Vincrisitne Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects >= 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)."
Primary Objective: To compare overall survival (OS) among subjects 60 years of age and older with newly diagnosed ALL who receive Marqibo versus standard vincristine as a component of multi-agent induction, intensification, and maintenance chemotherapy. The study is powered for superiority.
Study Design and Methodology: Eligible subjects will be randomized to a standardized and widely accepted combination chemotherapy regimen containing either VSI or Marqibo. Treatment will be divided into induction, intensification, and maintenance phases of therapy. The sample size is event driven with a projected total enrollment of 350 to 400 patients.
About Marqibo
Marqibo is a novel, targeted Optisome(TM) encapsulated formulation product candidate of the FDA-approved anticancer drug vincristine. Talon has been primarily developing Marqibo for the treatment of adult, Ph- ALL. Vincristine, a microtubule inhibitor, is FDA-approved for ALL and is widely used as a single agent and in combination regimens for treatment for hematologic malignancies such as lymphomas and leukemias. Talon's encapsulation formulation is designed to provide prolonged circulation of the drug in the blood and accumulation at the tumor site. These characteristics are intended to increase the dose of vincristine delivered in a safe and effective manner.
About Talon Therapeutics
Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
In addition to Marqibo, the Company has additional pipeline opportunities some of which, like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.
Additional information on Talon Therapeutics can be found at www.talontx.com.
The Talon Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include without limitation, statements regarding Talon's ability to obtain accelerated approval of Marqibo for the treatment of adult Ph- ALL, the potential of Marqibo to be a safe and effective alternative for existing therapies, the timing of initiating Talon's proposed Phase 3 clinical trial of Marqibo, and the timing, progress and anticipated results of the clinical development of Marqibo and Talon's other product candidates. Such statements involve risks and uncertainties that could cause Talon's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Such risks and uncertainties include: that there can be no assurances that any of Talon's clinical and regulatory development efforts relating to Marqibo will be successful; that Talon's NDA for Marqibo will be accepted for filing by the FDA and, even if the NDA is accepted by the FDA, that it will be approved; that the data of the clinical trials of Marqibo will be sufficient to support approval by the FDA of the NDA for Marqibo; that the results of the clinical trials of Marqibo will support Talon's claims or beliefs concerning Marqibo's safety and effectiveness; that Talon will be able to secure the additional capital necessary to fund its product development programs, including Marqibo, to completion; Talon's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2010. Talon assumes no obligation to update these statements, except as required by law.
Contact:
Investor & Media Contacts:
Investor Relations Team
(650) 588-6641
investor.relations@talontx.com
Antwort auf Beitrag Nr.: 42.016.668 von waxweazle am 29.08.11 17:12:59über 1 Dollar haben wir dann im weeklychart ein Kaufsignal im MACD!
wow - das sind ja Super-News und gleich ein neuer Thread dazu, gefaellt mir gut, auch wenn ich sonst kein Freund bin von inflationaeren Thread-Eroeffnungen, egal ob ich dabei bin oder nicht.
Und dabei sind die Umsaetze noch nicht mal aufregend hoch, aber keiner hat es geschafft (ausser der Zeit an sich) die Talon mit solchen Umsaetzen auf der Verkaeferseite innerhalb eines Tages so runter zu pruegeln.
Das sagt (mir): Hier steht eine Menge Hoffnung im Raum und mit ansehlichem Aufaertsdruck Potential.
Neuer Thread, neues Glueck, haut rein (beim Lesen natuerlich)
Gruss,
GaneshMK
Und dabei sind die Umsaetze noch nicht mal aufregend hoch, aber keiner hat es geschafft (ausser der Zeit an sich) die Talon mit solchen Umsaetzen auf der Verkaeferseite innerhalb eines Tages so runter zu pruegeln.
Das sagt (mir): Hier steht eine Menge Hoffnung im Raum und mit ansehlichem Aufaertsdruck Potential.
Neuer Thread, neues Glueck, haut rein (beim Lesen natuerlich)
Gruss,
GaneshMK
Moin,
ich bin zwar der englischen Sprache mächtig, aber ich kann mit den Fachtermini nix anfangen ... kann einer von euch Begeisterten das mal für mich runterbrechen, was sich da Bahnbrechendes getan hat????
Ich will mich mitfreuen ...
danke
:-) Wally
ich bin zwar der englischen Sprache mächtig, aber ich kann mit den Fachtermini nix anfangen ... kann einer von euch Begeisterten das mal für mich runterbrechen, was sich da Bahnbrechendes getan hat????
Ich will mich mitfreuen ...
danke
:-) Wally
Trading Spotlight
Zitat von Wallaby11: Moin,
ich bin zwar der englischen Sprache mächtig, aber ich kann mit den Fachtermini nix anfangen ... kann einer von euch Begeisterten das mal für mich runterbrechen, was sich da Bahnbrechendes getan hat????
Ich will mich mitfreuen ...
danke
:-) Wally
also ich kann in den news nichts bahnbrechendes finden
ich glaube sonst hätten wir hier ganz andere kurse gesehen!
was für mich erstmal viel wichtiger ist, wo kommen neue gelder her? ich glaube da werden bestimmt
wieder neue aktien ausgegeben??? ja und das kennt man ja seit jahren, das wird den kurs mal
wieder stark belasten...was die altaktionäre dadurch schon an geld verloren haben, wird jeder
noch wissen der schon seit vielen jahren dabei ist..
$ 10.500.000. reichen keine 6 monate und zwei monate sind davon schon wieder rum.
natürlich bleibe ich weiterhin dabei! aber meine begeisterung hebe ich mir für die zulassung
auf..aktuell sehe ich dafür noch kein grund. ist nicht sehr lange her, da hatten wir auch kurse
weit über 1 dollar..und in wenigen tagen war alles wieder weg.
Zitat:
Ab 30. Juni 2011 verfügte das Unternehmen über liquide Mittel und available-for-sale Wertpapieren von $ 10.500.000.
Antwort auf Beitrag Nr.: 42.024.996 von aktienguru123 am 31.08.11 10:44:07was ist Dein Fazit?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +2,25 | |
| +2,63 | |
| -0,39 | |
| -1,23 | |
| +14,29 | |
| -1,43 | |
| -0,70 | |
| -0,92 | |
| -1,58 | |
| +0,43 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 133 | ||
| 82 | ||
| 52 | ||
| 32 | ||
| 31 | ||
| 27 | ||
| 26 | ||
| 14 | ||
| 13 | ||
| 10 |
